BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 24941982)

  • 21. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
    Barrientos J; Rai K
    Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
    Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
    Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
    Burger JA
    Curr Hematol Malig Rep; 2014 Mar; 9(1):44-9. PubMed ID: 24357428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
    Liu N; Hoogendoorn S; van de Kar B; Kaptein A; Barf T; Driessen C; Filippov DV; van der Marel GA; van der Stelt M; Overkleeft HS
    Org Biomol Chem; 2015 May; 13(18):5147-57. PubMed ID: 25849561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib and novel BTK inhibitors in clinical development.
    Akinleye A; Chen Y; Mukhi N; Song Y; Liu D
    J Hematol Oncol; 2013 Aug; 6():59. PubMed ID: 23958373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib: first global approval.
    Cameron F; Sanford M
    Drugs; 2014 Feb; 74(2):263-71. PubMed ID: 24464309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib.
    Charalambous A; Schwarzbich MA; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Bhatt V; Alejandro L; Michael A; Ganetsky A
    Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.